Curanex Pharmaceuticals (NASDAQ:CURX) Releases Quarterly Earnings Results

Curanex Pharmaceuticals (NASDAQ:CURX) issued its earnings results on Friday. The company reported ($0.12) earnings per share (EPS) for the quarter, FiscalAI reports.

Curanex Pharmaceuticals Stock Down 0.9%

Shares of Curanex Pharmaceuticals stock opened at $0.22 on Friday. Curanex Pharmaceuticals has a 12 month low of $0.18 and a 12 month high of $9.18. The stock has a market cap of $6.17 million and a PE ratio of -0.56. The business has a fifty day simple moving average of $0.24 and a 200-day simple moving average of $0.33.

Institutional Investors Weigh In On Curanex Pharmaceuticals

A hedge fund recently bought a new position in Curanex Pharmaceuticals stock. Citadel Advisors LLC bought a new stake in shares of Curanex Pharmaceuticals Inc (NASDAQ:CURX) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 64,067 shares of the company’s stock, valued at approximately $46,000.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Curanex Pharmaceuticals Company Profile

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.